Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
84.92B | 84.41B | 82.11B | 83.86B | 80.14B | 84.92B | Gross Profit |
19.91B | 20.28B | 16.86B | 18.48B | 21.05B | 17.22B | EBIT |
5.92B | 6.09B | 2.94B | 4.41B | 7.49B | 4.30B | EBITDA |
9.57B | 9.76B | 892.00M | 9.61B | 13.76B | 2.43B | Net Income Common Stockholders |
4.10B | 5.01B | -7.09B | 2.34B | 6.75B | -2.80B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
15.07B | 16.18B | 16.59B | 12.41B | 10.80B | 11.09B | Total Assets |
125.24B | 123.32B | 125.44B | 128.02B | 123.92B | 123.01B | Total Debt |
23.80B | 21.92B | 27.04B | 21.64B | 16.96B | 20.44B | Net Debt |
8.73B | 5.74B | 10.45B | 9.23B | 6.16B | 9.35B | Total Liabilities |
47.44B | 43.93B | 49.98B | 43.31B | 41.21B | 43.74B | Stockholders Equity |
76.84B | 78.29B | 74.39B | 80.49B | 78.85B | 75.80B |
Cash Flow | Free Cash Flow | ||||
0.00 | 5.06B | 2.84B | -1.89B | 1.50B | -1.74B | Operating Cash Flow |
0.00 | 12.01B | 6.87B | 773.00M | 6.57B | 7.83B | Investing Cash Flow |
0.00 | -5.71B | -3.96B | -2.62B | -1.65B | -7.42B | Financing Cash Flow |
0.00 | -6.88B | 1.26B | 3.28B | -5.65B | 1.67B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | ¥216.88B | 20.42 | 1.13% | 4.85% | 35.53% | ||
75 Outperform | ¥74.08B | 8.43 | 4.58% | 4.87% | 5.12% | ||
71 Outperform | ¥44.89B | 8.61 | 5.15% | 3.16% | ― | ||
66 Neutral | ¥60.54B | 9.73 | 4.56% | 3.21% | -1.94% | ||
66 Neutral | ¥48.14B | 14.82 | 2.02% | -3.73% | ― | ||
51 Neutral | $2.04B | -1.15 | -21.24% | 3.95% | 2.91% | -30.44% |
Sakai Chemical Industry Co., Ltd. announced that it has not acquired any of its own shares during the specified acquisition period from May 15, 2025, to May 31, 2025, despite having resolved to purchase up to 1,000,000 shares. The acquisition plan, which was approved by the Board of Directors, aimed to enhance shareholder value but has yet to be executed, leaving the total number of shares acquired at zero.
Sakai Chemical Industry Co., Ltd. has announced a decision by its Board of Directors to acquire up to 1,000,000 of its own shares, representing 6.17% of its total issued shares, excluding treasury shares. This move, which will take place between May 15, 2025, and November 30, 2025, aims to improve shareholder value per share and capital efficiency. The acquisition will be conducted through market purchases on the Tokyo Stock Exchange and the Off-Auction Own Share Repurchase Trading System. Following the acquisition, the company plans to cancel all the treasury shares acquired, further optimizing its capital structure.
Sakai Chemical Industry Co., Ltd. has announced a proposal to amend its Articles of Incorporation by reducing the maximum number of directors from 15 to 11. This change aims to enhance management agility and strengthen corporate governance by aligning the number of directors with the current operational needs, following improvements in their executive officer system introduced in 2021.
Sakai Chemical Industry Co., Ltd. reported a significant improvement in its financial performance for the fiscal year ending March 2025, with a 2.8% increase in net sales and a dramatic rise in operating profit by 107.1%. The company’s comprehensive income also turned positive, reflecting a strong recovery from the previous year’s losses, indicating a positive impact on its operations and market positioning.